Results 11 to 20 of about 32,807 (303)

Repurposing of Bromocriptine for Cancer Therapy

Frontiers in Pharmacology, 2018
Bromocriptine is an ergot alkaloid and dopamine D2 receptor agonist used to treat Parkinson’s disease, acromegaly, hyperprolactinemia, and galactorrhea, and more recently diabetes mellitus.
Ean-Jeong Seo, Yoshikazu Sugimoto, Henry Johannes Greten, Thomas Efferth   +3 more
doaj   +2 more sources

Bromocriptine and insulin sensitivity in lean and obese subjects

Endocrine Connections, 2016
Bromocriptine is a glucose-lowering drug, which was shown to be effective in obese subjects with insulin resistance. It is usually administered in the morning. The exact working mechanism of bromocriptine still has to be elucidated.
L Bahler, H J Verberne, E Brakema, R Tepaske, J Booij, J B Hoekstra, F Holleman   +6 more
doaj   +2 more sources

The Effects of Bromocriptine on Preventing Postpartum Flare in Systemic Lupus Erythematosus Patients from South China

Journal of Immunology Research, 2015
Objective. Prolactin plays an important role on the disease flare of postpartum SLE patients. 76 pregnant SLE patients were enrolled in this study to evaluate the efficacy of bromocriptine (an inhibitor of prolactin secretion) on preventing the ...
Qiu Qian, Liang Liuqin, Li Hao, Yuan Shiwen, Zhan Zhongping, Chen Dongying, Lian Fan, Xu Hanshi, Yang Xiuyan, Ye Yujin   +9 more
doaj   +2 more sources

Effect of Bromocriptine-QR (a Quick-Release Formulation of Bromocriptine Mesylate) on Major Adverse Cardiovascular Events in Type 2 Diabetes Subjects [PDF]

Journal of the American Heart Association : Cardiovascular and Cerebrovascular Disease, 2012
Background: Bromocriptine-QR (a quick-release formulation of bromocriptine mesylate), a dopamine D2 receptor agonist, is a US Food and Drug Administrration–approved treatment for type 2 diabetes mellitus (T2DM).
Blonde, Lawrence, Bohannon, Nancy, Cincotta, Anthony H., Gaziano, John Michael, Scranton, Richard, Vinik, Aaron   +5 more
core   +2 more sources

Bromocriptine treatment and outcomes in peripartum cardiomyopathy: the EORP PPCM registry. [PDF]

Eur Heart J
Background and Aims Peripartum cardiomyopathy (PPCM) remains a serious threat to maternal health around the world. While bromocriptine, in addition to standard treatment for heart failure, presents a promising pathophysiology-based disease-specific ...
van der Meer P, van Essen BJ, Viljoen C, Böhm M, Jackson A, Hilfiker-Kleiner D, Hoevelmann J, Mebazaa A, Farhan HA, Goland S, Ouwerkerk W, Petrie MC, Seferović PM, Tromp J, Sliwa K, Bauersachs J.   +15 more
europepmc   +2 more sources

Bromocriptine inhibits proliferation in the endometrium from women with adenomyosis

Frontiers in Endocrinology, 2023
ObjectiveBromocriptine treatment has been shown to reduce menstrual bleeding and pain in women with adenomyosis in a pilot clinical trial. The underlying mechanism contributing to the treatment effect is however unknown.
Yiqun Tang, Sakthivignesh Ponandai-srinivasan, Caroline Frisendahl, Johanna K. Andersson, Dora Pavone, Elizabeth A. Stewart, Parameswaran Grace Luther Lalitkumar, Eberhard Korsching, Nageswara Rao Bogavarappu, Kristina Gemzell-Danielsson   +9 more
doaj   +1 more source

Estrogen receptor α/prolactin receptor bilateral crosstalk promotes bromocriptine resistance in prolactinomas

International Journal of Medical Sciences, 2020
Prolactinomas are the most common type of functional pituitary adenoma. Although bromocriptine is the preferred first line treatment for prolactinoma, resistance frequently occurs, posing a prominent clinical challenge. Both the prolactin receptor (PRLR)
Zhengzheng Xiao, Xiaoli Yang, Kun Zhang, Zebin Liu, Zheng Shao, Chaojun Song, Xiaobin Wang, Zhengwei Li   +7 more
semanticscholar   +1 more source

Is Abrupt Withdrawal of Benzodiazepines a Risk Factor for Neuroleptic Malignant Syndrome? A Case Report With Single-Dose Haloperidol. [PDF]

Clin Case Rep
ABSTRACT Neuroleptic malignant syndrome (NMS) is a rare but life‐threatening reaction associated with the use of dopamine‐modulating agents, which presents with symptoms like high fever, muscle rigidity, and autonomic instability. It is known that both the use of dopamine receptor antagonists and the sudden withdrawal of dopamine receptor agonists can ...
Abbasi B, Elyasi F, Aliyali M.
europepmc   +2 more sources

Protective Role of Sarpogrelate in Combination with Bromocriptine and Cabergoline for Treatment of Diabetes in Alloxan-induced Diabetic Rats

Current Therapeutic Research, 2021
: Background: Although dopamine D2 receptor agonists, bromocriptine and cabergoline, are notable medications in the treatment of Parkinsonism, hyperprolactinemia, and hyperglycemia, there is an identified relationship between the utilization of D2-like ...
Mohammed Fouad Shalaby, MD, Hekma A. Abd El Latif, PhD, Mohamed El Yamani, PhD, May Ahmed Galal, PhD, Sherifa Kamal, PhD, Ikhlas Sindi, PhD   +5 more
doaj   +1 more source

Cardiac valvular abnormalities associated with use and cumulative exposure of cabergoline for hyperprolactinemia: the CATCH study

BMC Endocrine Disorders, 2020
Background Whether lower dose cabergoline therapy for hyperprolactinemia increases risk of valvular dysfunction remains controversial. We examined valvular abnormalities among asymptomatic adults with hyperprolactinemia treated with dopamine agonists ...
Amer Budayr, Thida C. Tan, Joan C. Lo, Jonathan G. Zaroff, Grace H. Tabada, Jingrong Yang, Alan S. Go   +6 more
doaj   +1 more source